- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Ranbaxy acquires U.S. rights to 13 Bristol-Myers Squibb dermatology brands
Bombay, India - Ranbaxy Laboratories Inc., a wholly owned subsidiary of Bombay-based Ranbaxy Laboratories Ltd., has acquired the U.S. rights to a group of 13 dermatology brands from Bristol-Myers Squibb Co. for $26 million, Domain-b.com reports.
Bombay, India - Ranbaxy Laboratories Inc., a wholly owned subsidiary of Bombay-based Ranbaxy Laboratories Ltd., has acquired the U.S. rights to a group of 13 dermatology brands from Bristol-Myers Squibb Co. for $26 million, Domain-b.com reports.
According to the Domain-b report, the acquisition enables the company to establish an immediate North American presence in disease segments such as dermatitis, psoriasis, scabies and anti-fungal, in addition to acne, where the company currently has a popular brand, Sotret Isotretinoin Capsules.
In addition, the acquisition creates a broader platform for the introduction of line extensions and additional brands, which will be marketed in the United States under the Ranbaxy Laboratories label.
